AbbVie’s RINVOQ (upadacitinib) Receives the EC’s Approval for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

 AbbVie’s RINVOQ (upadacitinib) Receives the EC’s Approval for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis

Shots:

  • The approval is based on P-III SELECT rheumatoid arthritis program which involves assessing of RINVOQ vs placebo, MTX or adalimumab in 4,400 patients in five pivotal studies i.e SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY
  • P-III study results: SELECT COMPARE- RINVOQ + MTX vs PBO + MTX (29% vs 6%) & Humira
    + MTX (29% vs 18%) @12wks; SELECT-MONOTHERAPY- RINVOQ vs MTX @monothx achieved remission (28% vs 8%) @14wks.; SELECT-EARLY (48% vs 18%) @24 wks.; inhibition of structural joint damage progression (0.1 vs 0.7) @24wks., (0.2 vs 0.9) @26 wks.
  • RINVOQ (upadacitinib) is a once-daily selective and reversible JAK inhibitor and may be used as monotherapy or in combination with methotrexate (MTX)

Click here to read full press release/ article | Ref: AbbVie| Image: Signbox

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post